The Rats developing genetic hypertension, such as the OkamotoAoki strain of spontaneously hypertensive rat (SHR), provide opportunities for insight into mechanisms involved in the pathogenesis of essential hypertension in humans. Crosstransplantation studies indicate that the kidneys play a pivotal role in the development of hypertension in genetically hypertensive rats (1-3). Alterations in renal vascular resistance, glomerular filtration rate, renal blood flow, and sodium and water retention have been described in 6-to 8-week-old SHRs compared with age-matched control Wistar-Kyoto rats (WKYs) (4-6). The abnormalities in renal hemodynamics and function become less pronounced as the hypertension advances to an established phase in 12-week-old SHRs (7, 8) .
Rats developing genetic hypertension, such as the OkamotoAoki strain of spontaneously hypertensive rat (SHR), provide opportunities for insight into mechanisms involved in the pathogenesis of essential hypertension in humans. Crosstransplantation studies indicate that the kidneys play a pivotal role in the development of hypertension in genetically hypertensive rats (1) (2) (3) . Alterations in renal vascular resistance, glomerular filtration rate, renal blood flow, and sodium and water retention have been described in 6-to 8-week-old SHRs compared with age-matched control Wistar-Kyoto rats (WKYs) (4) (5) (6) . The abnormalities in renal hemodynamics and function become less pronounced as the hypertension advances to an established phase in 12-week-old SHRs (7, 8) . Genetic cosegregation studies reveal a direct relationship between increased renal vascular resistance and arterial hypertension (9) . The mechanism(s) responsible for increased vascular resistance and reactivity have been the subject of intense investigation. Increased renal vascular resistance in adult animals is proportional to the increase in arterial pressure and may represent an appropriate autoregulatory response (7) . In contrast, the reduced renal blood flow and glomerular filtration rate in young SHRs with minimally elevated arterial pressure are consistent with the participation of vasoconstrictor factor(s).
Although circulating and intrarenal levels of renin are considered normal in SHRs, several lines of evidence support the notion that the renin-angiotensin system exerts a stronger than normal influence on the renal circulation in young SHR(s). Acute and chronic inhibition of angiotensinconverting enzyme prevents the development of hypertension in young SHR(s) (10) . In previous studies we observed that renal vascular responses to angiotensin II (Ang-IT) are exaggerated in young SHRs compared with those in WKYs (10) (11) (12) (13) . This strain difference was not due to differences in the affinity and/or density of the Ang-II receptors found in the renal vasculature but rather was due to identified interactions with other vasoactive substances (12, 13) .
The increased vasoconstriction could be caused by reduced offsetting activity of a vasodilator system. Several renal vasodilators, such as prostaglandins E2 and I2 and the dopamine (DA1)-agonist fenoldopam, could not buffer the Ang-TIinduced vasoconstriction in the kidneys of 6-to 8-week-old SHRs. The same vasodilator agents were, however, able to almost completely abolish the Ang-II effect in kidneys of age-matched WKYs (13) (14) (15) . The abnormality seemed specific to activators of the cAMP messenger system. Receptor agonists leading to increased nitric oxide production and activation of the cGMP pathway were equally effective in normotensive and hypertensive strains (13, 14) .
The present study examined the mechanisms responsible for 5 ,ul/min.
The following drugs were used in this study: Ang-II, NaF, and indomethacin (Sigma), fenoldopam (SmithKline Beecham), and cholera toxin (Biomol, Plymouth Meeting, PA). Ang-I1 (2 rg) was injected into the left renal artery either alone or in a mixture with fenoldopam (10 iqg). The G protein activators NaF and cholera toxin were infused at low doses (13 qg/min and 1.3 ,ug/min, respectively); they did not affect basal renal blood flow or arterial pressure. The intrarenal administration of the G protein activators was started 2 min before Ang-IT was injected either alone or with fenoldopam and was continued until the end of each 2-min recording. The time interval between Ang-II injections was 15 min. To avoid treatment interactions, only one G protein activator was given to an animal. Ang-II responsiveness was tested between infusions of NaF or cholera toxin. In all cases, Ang-II produced a similar decrease in renal blood flow. Thus, G protein activators produced specific changes in the responsiveness of the renal vasculature.
The data-acquisition system consisted of an IBM PCcompatible computer and a 12-bit analog-to-digital converter (11, 12) . Each recording was started when Ang-Il was introduced into the renal artery infusion line. The outputs of the transducers monitoring arterial pressure and renal blood flow were sampled at a rate of 100 samples per sec for a period of 2 min. Data were averaged to obtain sec-by-sec estimates of renal blood flow and arterial pressure, and these averages were used to estimate renal vascular resistance each sec. The renal blood flow, arterial pressure, and renal vascular resistance values were normalized and expressed as a percentage of baseline values. The baseline was calculated separately for each injection using the mean values of the corresponding variables observed during the time between the introduction of Ang-II into the infusion line and the onset of the renal vascular response. Plots of normalized arterial pressure, renal blood flow, and renal vascular resistance as a function of time were prepared by using the SIGMAPLOT software package. Nonlinear least-squares estimation was used to fit a smooth curve to each blood flow and vascular resistance recording as described (11) . The best-fit curve was used to calculate the maximum response and kinetic parameters, such as the time required to reach the maximum response and the half-times for constriction and recovery.
Statistical analyses were done by using the Multivariate Generalized Linear Hypothesis module of the SYSTAT software package. Statistical analyses of the maximum changes in renal blood flow gave similar results, regardless of whether these changes were expressed as a percentage of the baseline or as absolute values. P < 0.05 was considered statistically significant.
RESULTS
Baseline renal hemodynamic data are summarized in Table 1 . Seven-week-old SHRs were moderately hypertensive compared with age-matched WKY controls. In SHRs, basal renal flow was reduced and renal vascular resistance was increased in agreement with previous results (5, 11) . Indomethacin affected neither arterial pressure nor renal blood flow in WKYs and SHRs, in accordance with earlier results (11) .
Injection of Ang-II into the renal artery produced a transient decrease in renal blood flow and an increase in renal vascular resistance, without affecting systemic arterial pressure. Because arterial pressure was constant, local changes in renal blood flow were associated with reciprocal changes in renal vascular resistance (data not shown). Representative examples of the renal vascular response to Ang-I1 are shown in Fig. 1 . The maximum vasoconstriction caused by 2 -g of Ang-I1 was similar in WKYs and SHRs. Renal blood flow was reduced by 44 ± 2 vs. 45 ± 2% (P > 0.6), in close agreement with previous observations (11, 12) .
Fenoldopam, a dopamine DAl-receptor agonist, was coadministered with Ang-II intrarenally to determine whether receptor-mediated stimulation of intracellular cAMP can buffer the vasoconstrictor effect of Ang-II. The data in Fig. 1A show that fenoldopam attenuated 50% of the transient renal vasoconstriction produced by Ang-II in WKY kidneys. The maximum decrease in renal blood flow observed at 29 sec after injection was reduced from -52% to -31% of basal renal blood flow. The buffering effect of fenoldopam could be blocked by coadministration of the receptor-antagonist SCH-23390 in a dose-related manner, indicating selective activation ofvascular DAt receptors. On the other hand, fenoldopam was ineffective in SHR kidneys (Fig. IB) . The maximum response to the mixture of Ang-II and fenoldopam did not differ from that of Ang-IT alone in the genetically hypertensive strain. Statistical analysis using the best-fitting curve model described earlier in Materials and Methods confirmed that fenoldopam significantly reduced the maximum vasoconstriction produced by Ang-II in seven WKYs (-30 ± 2% vs. -45 + 3% basal renal blood flow, P < 0.001), but it had no effect in seven SHRs (-44 ± 2%o vs. -45 ± 2%, P > 0.7) (Fig. 2) .
The kinetics describing the transient response to Ang-II when administered alone and coadministered with fenoldopam did not differ between SHR and WKY (Table 2) . Interestingly, fenoldopam shortened the half-time of recovery from the Ang-Il-induced vasoconstriction similarly in WKYs (from 75 + 3 to 64 ± 4 sec, P < 0.05) and SHRs (from 71 + 3 to 64 ± 2 sec, P < 0.05), even though a strain difference was observed in the magnitude of the maximum response (Fig. 2) Fenoldopam had no effect on the time to maximum vasoconstriction (29 ± 1 vs. 29 ± 1 sec) in both strains.
Further studies were done to gain insight into the mechanism(s) responsible for this abnormality in vascular reactivity. We investigated whether the strain difference in the ability of fenoldopam to buffer the Ang-II-induced renal vasoconstriction could be related to the efficiency of coupling of DAl receptors to G proteins. For this reason, the renal vasculature was exposed to NaF, a general activator of G proteins (17) (18) (19) . In the absence of a vasodilator agent, NaF did not affect the decrease in renal blood flow induced by Ang-II in WKYs (-46 ± 4% vs. -45 ± 2%, P > 0.7) or in SHRs (-45 ± 2% vs. -45 ± 3%, P > 0.6). An important finding was that a NaF effect was observed when fenoldopam was injected in combination with Ang-II. The vasoconstriction produced by Ang-II was (Figs. 1 and  2 ). This result contrasts with the earlier data for the hypertensive strain showing that fenoldopam was ineffective without NaF.
To determine whether or not a specific family of G proteins was involved in the buffering effect, other animals were treated with cholera toxin, a selective activator of G, proteins (17) (18) (19) .
Representative examples of the renal vascular response to Ang-II injected alone and in mixture with fenoldopam before and during cholera toxin infusion are shown in Fig. 3 . In WKYs, fenoldopam blunted the Ang-1I-induced vasoconstriction (-31 ± 2% vs. -44 ± 3%, P < 0.001) (Figs. 3A and 4) . Cholera toxin infusion enhanced the buffering effect of fenoldopam (-19 ± 3% vs. -31 ± 2%, P < 0.001) (Figs. 3A  and 4 ). In SHRs, coadministration of fenoldopam with Ang-II did not alter the renal vasoconstriction produced by (-44 ± 3% vs. -45 ± 4%) (Fig. 4) . In marked contrast, simultaneous exposure to cholera toxin unmasked a buffering effect of fenoldopam in the hypertensive strain. As is shown in Fig. 3B , the transient decrease in renal blood flow was clearly blunted during infusion of cholera toxin as compared with the administration of Ang-II plus fenoldopam without cholera toxin. The average maximum vasoconstriction was significantly reduced when the G protein stimulator was administered (-31 ± 2% vs. -45 ± 4%, P < 0.01) (Figs. 3B and 4) .
The amplifying effect of NaF and cholera toxin appeared specific for an interaction between the DA1 receptor and Gs protein. The agents administered into the renal artery by themselves had no demonstrable effect on basal renal blood flow, and neither affected the renal vasoconstriction produced by Ang-II in either strain of rat. In the absence of fenoldopam, Ang-II-induced decreases in renal blood flow were similar before and during administration of NaF or cholera toxin.
DISCUSSION
The present study provides important information about the mechanism(s) by which Ang-II enhances vasoconstriction in kidneys of rats developing hypertension of genetic origin. Transient changes in the renal vasculature were monitored after bolus administration of Ang-I1 into the renal artery of 7-week-old SHRs with age-matched WKYs serving as normotensive controls. The applied technique and data analysis permitted estimation of local responses of the renal vasculature to vasoactive agents without systemic complications. As a result, a comprehensive evaluation of intrarenal mechanisms governing the renal microcirculation in vivo was feasible (11) .
Recent studies by our laboratory and other investigators (11, 12, 20) have established that kidneys of young SHRs exhibit exaggerated reactivity to Ang-I1 compared with normotensive WKY controls. The fact that treatment of the rats with indomethacin, a cyclooxygenase inhibitor, increased the Ang-1I-induced vasoconstriction in WKYs and abolished the strain difference in vascular reactivity suggests that the action of endogenous prostaglandins affords protection in WKY, but not in SHR, kidneys (11) .
In support of this hypothesis, intrarenal infusion of authentic vasodilator prostaglandins E2 and 12 or of their respective receptor agonists viprostol and iloprost failed to protect kidneys of the SHR from the Ang-II-induced vasoconstriction, whereas the same prostanoids effectively blunted -50% of the effect of Ang-II in WKY kidneys (14) . Similar to prostaglandins, the dopamine DAl-receptor agonist fenoldopam significantly buffered the Ang-II-induced vasoconstriction in WKY, but not in SHR, kidneys (16)-. On the contrary, acetylcholine and bradykinin, representing another class of renal vasodilators, effectively attenuated the vasoconstrictor effect of Ang-II in a dose-dependent fashion in the kidneys of both SHRs and WKYs (16) . The actions of fenoldopam and prostaglandins are initiated by binding to specific receptors on the surface of vascular smooth muscle cells. The receptor-ligand complex stimulates the cAMP pathway through activation of GTPbinding stimulatory G, proteins. On the other hand, acetylcholine and bradykinin primarily act in vivo through endothelial-derived nitric oxide to activate the cGMP pathway. Thus, the defect seemed to be localized to the cAMP signaling pathway that would normally respond to several different receptor agonists.
Our previous studies evaluated the role of cAMP production as a mechanism responsible for the failure of fenoldopam and prostaglandins to buffer the Ang-II effect in SHRs. In vivo activation of the intracellular cAMP pathway in the renal resistance vessels was tested by using forskolin (adenylyl cyclase activation independently of receptor binding) or by administering dibutyryl-cAMP (cell-membrane permeable form of cAMP) into the renal artery (16) . Both cAMPelevating agents buffered the Ang-II-induced vasoconstriction. A similar degree of protection was provided in WKY and SHR kidneys. These observations indicate that renal vasodilators acting through receptor coupling to activate the cAMP pathway fail to buffer the Ang-IT-induced vasoconstriction in SHRs. The defective event in this abnormal transmission of the signal(s) appears to be localized to a step proximal to activation of adenylyl cyclase.
The intracellular events preceding adenylyl cyclase activa- Attenuated generation of cAMP within the renal vasculature could result in increased renal vascular resistance, and a similar defect in cAMP generation in renal tubules could lead to increased sodium retention. Both of these renal abnormalities are associated with the initiation and development of hypertension (4, 5) .
Further support for our findings and conclusions derives from a study comparing the function of G proteins in membranes of mesenteric arteries isolated from SHRs and WKYs. Agents that activate the cAMP pathway through receptor coupling to G proteins caused a smaller stimulatory response of cAMP generation in SHRs (26) . However, when forskolin was used to stimulate adenylyl cyclase independent of activation of cell-surface receptors, the cAMP levels were increased to an equal extent in SHR and WKY membranes. In addition, no strain difference was found in the G protein levels of this tissue, as evidenced by immunoblotting.
In our studies, fenoldopam facilitated the recovery from transient vasoconstriction after the activation of Ang-1I receptors. The half-time of recovery after injection of the mixture of fenoldopam and Ang-IT was similar in SHRs and WKYs, even though the magnitude of the maximum response was 2-fold larger in SHRs. A similar observation was made in earlier studies (12, 14) when several doses of fenoldopam and prostaglandins were tested. To explain these results we postulated a dual mechanism of action of renal vasodilators against the Ang-II-induced vasoconstriction. One part of this mechanism is considered dependent on cAMP activation and thereby impacts on the magnitude of the maximum renal vascular response. The other part is related to the rate of recovery and may be related to the rate of dephosphorylation of myosin. SHRs appear to be defective in the first, but not the second, mechanism (12, 14) . Our present results provide evidence to support this hypothesis. The combination of G protein activation and fenoldopam did not provide any additional change of the recovery rate, although the magnitude of the response to Ang-Il was buffered.
In conclusion, vasodilators that activate the cAMP intracellular signaling pathway are ineffective in counteracting the vasoconstrictor effect of Ang-II in the renal vasculature of young SHRs. The cause of this defect is probably related to a deficient interaction between the cell-surface receptors of these agents and their respective G, proteins. Such a generalized defect of the renal vasculature could be a major contributor to the development of genetic hypertension.
